7-Ketolithocholic acid (Synonyms: 7-KLCA, 7-keto LCA, 7-oxo LCA, 7-keto Lithocholate, 7-oxo Lithocholate, 7-oxo Lithocholic Acid, NSC 226118) |
| Catalog No.GC39474 |
7-Ketolithocholic acid (3α-hydroxy-7-oxygen-5β-cholic acid) is a kind of bile acid, 7-Ketolithocholic acid can be absorbed, 7-ketolithocholic acid inhibits the production of endogenous bile acid, and can affect the secretion of biliary cholesterol.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4651-67-6
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
7-Ketolithocholic acid (3α-hydroxy-7-oxygen-5β-cholic acid) is a kind of bile acid, 7-Ketolithocholic acid can be absorbed, 7-ketolithocholic acid inhibits the production of endogenous bile acid, and can affect the secretion of biliary cholesterol[1，2].
After 7-ketolithocholic acid (400 mg/day) was administered orally for 14 days, biliary bile acid composition changed: The proportion of cholic acid decreased (from 45% to 19%), deoxycholic acid decreased (from 15% to 10%), chenodeoxycholic acid increased markedly (from 36% to 59%), ursodeoxycholic acid increased (from 36% to 59%), ursodeoxycholic acid increased (from 2% to 7%), and lithocholic acid increased (from 2% to 5%), while only trace amounts of 7-ketolithocholic acid were detected. During this treatment, the biliary lithogenic index fell from 2.6 to 0.9 and was accompanied by a pronounced drop in biliary cholesterol concentration[2].
References:
[1]. Choucair I, Nemet I, et,al. Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. J Lipid Res. 2020 Feb;61(2):159-177. doi: 10.1194/jlr.RA119000311. Epub 2019 Dec 9. PMID: 31818878; PMCID: PMC6997600.
[2]. Salen G, Verga D, et,al. Effect of 7-ketolithocholic acid on bile acid metabolism in humans. Gastroenterology. 1982 Aug;83(2):341-7. PMID: 7084613.
| Clinical experiment [1]: | |
Animal models | 5 male subjects with gallstones (mean age, 55 years old) |
Preparation Method | 400 mg/day of uniformly labeled 7-ketolithocholic acid (sp act, 1000 * 100 dpm/mg) was fed to each patient daily for 2 wk and the specific activities of chenodeoxycholic acid and ursodeoxycholic acid in bile were measured every other day. |
Dosage form | 400 mg/day for 2 week Intravenous injection |
Applications | 7-ketolithocholic acid is absorbed, and suppresses endogenous bile acid production and biliary cholesterol secretion. |
References: | |
| Cas No. | 4651-67-6 | SDF | |
| Synonyms | 7-KLCA, 7-keto LCA, 7-oxo LCA, 7-keto Lithocholate, 7-oxo Lithocholate, 7-oxo Lithocholic Acid, NSC 226118 | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])C(C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O | ||
| Formula | C24H38O4 | M.Wt | 390.56 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5604 mL | 12.8021 mL | 25.6043 mL |
| 5 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL |
| 10 mM | 0.256 mL | 1.2802 mL | 2.5604 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *